139 related articles for article (PubMed ID: 10937806)
1. Screening for abnormalities of the protein C anticoagulant pathway using the ProC Global assay. Results of a European multicenter evaluation.
Toulon P; Halbmeyer WM; Hafner G; Schmitt Y; Randgard B; Odpadlik M; Van Den Eynden C; Wagner C
Blood Coagul Fibrinolysis; 2000 Jul; 11(5):447-54. PubMed ID: 10937806
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of the ProC global assay for protein C pathway abnormalities. clinical experience in 899 unselected patients with venous thromboembolism.
Toulon P; Adda R; Perez P
Thromb Res; 2001 Oct; 104(2):93-103. PubMed ID: 11672753
[TBL] [Abstract][Full Text] [Related]
3. Screening for risk factors for thrombosis using a new generation of assays developed to evaluate the functionality of the protein C anticoagulant pathway.
Toulon P; Perez P
Hematol Oncol Clin North Am; 2000 Apr; 14(2):379-89. PubMed ID: 10806561
[TBL] [Abstract][Full Text] [Related]
4. Modification of the ProC Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation.
Quincampoix JC; Legarff M; Rittling C; Andiva S; Toulon P
Blood Coagul Fibrinolysis; 2001 Oct; 12(7):569-76. PubMed ID: 11685046
[TBL] [Abstract][Full Text] [Related]
5. [Clinical usefulness of global assays of the anticoagulant pathway of protein C].
Toulon P
Ann Biol Clin (Paris); 2001; 59(5):545-50. PubMed ID: 11602384
[TBL] [Abstract][Full Text] [Related]
6. ProC Global assay in the evaluation of women with history of severe preeclampsia or HELLP syndrome.
Heilmann L; von Tempelhoff GF; Pollow K
Clin Appl Thromb Hemost; 2002 Oct; 8(4):319-24. PubMed ID: 12518722
[TBL] [Abstract][Full Text] [Related]
7. ProC Global: the first functional screening assay for the complete protein C pathway.
Dati F; Hafner G; Erbes H; Prellwitz W; Kraus M; Niemann F; Noah M; Wagner C
Clin Chem; 1997 Sep; 43(9):1719-23. PubMed ID: 9299966
[TBL] [Abstract][Full Text] [Related]
8. ProC global: a new automated screening assay for the evaluation of total function of the protein C system.
Dragoni F; Tormene D; Simioni P; Arcieri P; Avvisati G; Girolami A
Clin Appl Thromb Hemost; 2001 Oct; 7(4):351-5. PubMed ID: 11697723
[TBL] [Abstract][Full Text] [Related]
9. A new chromogenic assay (HemosIL ThromboPath) is sensitive to major prothrombotic risk factors affecting the protein C pathway. Results of a multicenter study.
Toulon P; Smirnov M; Triscott M; Safa O; Biguzzi E; Bouziane K; Tripodi A
Thromb Res; 2009 May; 124(1):137-43. PubMed ID: 19157524
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Pro-C global for identification of defects in protein C/S anticoagulant pathway.
Bin Hanif T; Anwar J; Idrees M
J Ayub Med Coll Abbottabad; 2011; 23(1):89-91. PubMed ID: 22830156
[TBL] [Abstract][Full Text] [Related]
11. The reduced sensitivity of the ProC Global test in protein S deficient subjects reflects a reduction in the associated thrombotic risk.
Gemmati D; Serino ML; Tognazzo S; Ongaro A; Moratelli S; Gilli G; Forini E; De Mattei M; Scapoli GL
Blood Coagul Fibrinolysis; 2001 Dec; 12(8):691-7. PubMed ID: 11734670
[TBL] [Abstract][Full Text] [Related]
12. "ProC Global": a functional screening test that predicts recurrent venous thromboembolism.
Grand'Maison A; Bates SM; Johnston M; McRae S; Ginsberg JS
Thromb Haemost; 2005 Mar; 93(3):600-4. PubMed ID: 15735816
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a new screening assay ProC Global for identification of defects in the protein C/protein S anticoagulant pathway.
Ruzicka K; Kapiotis S; Quehenberger P; Handler S; Pabinger-Fasching I; Mannhalter C; Jilma B; Speiser W
Thromb Res; 1997 Sep; 87(6):501-10. PubMed ID: 9330432
[TBL] [Abstract][Full Text] [Related]
14. Protein C global assay in the evaluation of women with idiopathic pregnancy loss.
Sarig G; Lanir N; Hoffman R; Brenner B
Thromb Haemost; 2002 Jul; 88(1):32-6. PubMed ID: 12152673
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a global screening assay for the investigation of the protein C anticoagulant pathway.
Rimmer JE; Cooper PC; Brookfield CJ; Preston FE; Makris M
Clin Lab Haematol; 2000 Dec; 22(6):351-4. PubMed ID: 11318801
[TBL] [Abstract][Full Text] [Related]
16. Coagulation assay with improved specificity to factor V mutants insensitive to activated protein C.
Kraus M; Zander N; Fickenscher K
Thromb Res; 1995 Nov; 80(3):255-64. PubMed ID: 8578552
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of screening tests for defects in the protein C pathway: commercial kits lack sensitivity and specificity.
Gardiner C; Cooper PC; Makris M; Mackie IJ; Malia RG; Machin SJ
Blood Coagul Fibrinolysis; 2002 Mar; 13(2):155-63. PubMed ID: 11914658
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
Gessoni G; Valverde S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
[TBL] [Abstract][Full Text] [Related]
19. The impact of oral anticoagulant therapy, factor VIII level and quality of factor V-deficient plasma on three commercial methods for activated protein C resistance.
Chitolie A; Lawrie AS; Mackie IJ; Harrison P; Machin SJ
Blood Coagul Fibrinolysis; 2001 Apr; 12(3):179-86. PubMed ID: 11414631
[TBL] [Abstract][Full Text] [Related]
20. An abnormal ProC Global test result is associated with an increased risk of venous thromboembolism independent of test sensitivity for protein C pathway abnormalities.
Toulon P; Perez P; Rapp J; Adda R
Thromb Haemost; 2007 Jul; 98(1):228-33. PubMed ID: 17598017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
